Do you want to read an article? Please log in or register.
Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease
Inflamm Bowel Dis.
Targownik LE, Benchimol EI, Witt J, Bernstein CN, Singh H, Lix L, Tennakoon A, Zubieta AA, Coward S, Jones J, Kuenzig E, Murthy SK, Nguyen GC, Peña-Sánchez JN, Kaplan G
doi: 10.1093/ibd/izz063.
Inflammatory Bowel Disease
Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients
J Crohns Colitis.
de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel MGVM, Römkens TEH, West RL, Jansen JM, Hoentjen F
doi: 10.1093/ecco-jcc/jjaa012.
Inflammatory Bowel Disease
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry
Inflamm Bowel Dis.
Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S,
Gisbert JP
doi: 10.1093/ibd/izz192.
Inflammatory Bowel Disease
Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicenter Study
J Crohns Colitis.
Chavarría C, Casanova MJ, Chaparro M, Barreiro-de Acosta M, Ezquiaga E, Bujanda L, Rivero M, Argüelles-Arias F, Martín-Arranz MD, Martínez-Montiel MP, Valls M, Ferreiro-Iglesias R, Llaó J, Moraleja-Yudego I, Casellas F, Antolín-Melero B, Cortés X, Plaza R, Pineda JR, Navarro-Llavat M, García-López S, Robledo-Andrés P, Marín-Jiménez I, García-Sánchez V, Merino O, Algaba A, Arribas-López MR, Banales JM, Castro B, Castro-Laria L, Honrubia R, Almela P, Gisbert JP
doi: 10.1093/ecco-jcc/jjz024.
Inflammatory Bowel Disease
Pre-treatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients with Inflammatory Bowel Diseases
Gastroenterology.
Kochar B, Cai W, Cagan A, Ananthakrishnan AN
doi: 10.1053/j.gastro.2020.02.032.
COMMENTED
Inflammatory Bowel Disease
Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Gastroenterology.
Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD
doi: 10.1053/j.gastro.2020.05.032.
Inflammatory Bowel Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Lancet Gastroenterol Hepatol.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group
doi: 10.1016/S2468-1253(19)30012-3.
Inflammatory Bowel Disease
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
J Crohns Colitis.
Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN
doi: 10.1093/ecco-jcc/jjaa050.
Inflammatory Bowel Disease
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
United European Gastroenterol J.
Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A
doi: 10.1177/2050640620929133.